Aidebaike Delida, Gong Hailong, Xia Yun, Jing Guoqing, Liu Huifan, Zhou Huimin, Wu Die, Zuo Jing, Yang Cheng, Wang Xing, Dong Yingyue, Yan Jie, Chen Xue, Lei Zihan, Liang Junjie, Wu Xiaojing, Song Xuemin
Research Centre of Anesthesiology and Critical Care Medicine, Zhongnan Hospital of Wuhan University, Wuhan, Hubei Province 430071, China.
Department of Anesthesiology, Renmin Hospital of Wuhan University, Wuhan, Hubei Province 430060, China.
Phytomedicine. 2025 Sep;145:156957. doi: 10.1016/j.phymed.2025.156957. Epub 2025 Jun 14.
Sepsis-induced lung injury (SILI) is marked by excessive inflammation and apoptosis, posing considerable therapeutic problems owing to the scarcity of targeted therapy. Tanshinone IIA (TanIIA), a bioactive molecule extracted from Salvia miltiorrhiza, demonstrates potential in regulating inflammatory pathways and enhancing cellular resilience.
This study comprehensively examined the therapeutic mechanisms of TanIIA in SILI by an integrated methodology that incorporates network pharmacology, molecular docking, and comprehensive experimental validation.
Network pharmacology and WGCNA analysis of GSE239388 revealed possible treatment targets for TanIIA. Computational analysis utilizing molecular docking techniques and molecular dynamics simulations validated a stable intermolecular connection between TanIIA and the vascular endothelial growth factor receptor 2. TanIIA's therapeutic effectiveness was evaluated in vivo using septic mouse model. BEAS-2B cells treated with LPS in vitro were employed to elucidate the underlying mechanisms. Western blotting, qRT-PCR, immunohistochemistry, flow cytometry, and mitochondrial function assays were performed to evaluate gene expression, apoptosis, and mitochondrial functionality.
VEGFR2 was identified as a critical therapeutic target of TanIIA in SILI. Treatment with TanIIA significantly enhanced survival rates, mitigated lung histopathological damage, and decreased levels of pro-inflammatory cytokines in CLP-induced septic mice. Mechanistically, TanIIA suppressed the VEGFR2-PI3K-AKT signaling pathway, preserving mitochondrial integrity and inhibiting apoptosis. Additional validation was obtained using LPS-treated BEAS-2B epithelial cells, reinforcing the initial findings.
TanIIA provides protective effects against SILI by specifically targeting VEGFR2 and inhibiting the PI3K/AKT signaling pathway, which helps maintain mitochondrial homeostasis and reduces apoptosis.
脓毒症诱导的肺损伤(SILI)以过度炎症和细胞凋亡为特征,由于缺乏靶向治疗方法,带来了相当大的治疗难题。丹参酮IIA(TanIIA)是从丹参中提取的一种生物活性分子,在调节炎症信号通路和增强细胞抗逆性方面显示出潜力。
本研究采用网络药理学、分子对接和综合实验验证相结合的方法,全面探究TanIIA对SILI的治疗机制。
对GSE239388进行网络药理学和加权基因共表达网络分析(WGCNA),揭示TanIIA可能的治疗靶点。利用分子对接技术和分子动力学模拟进行计算分析,验证TanIIA与血管内皮生长因子受体2(VEGFR2)之间稳定的分子间连接。在脓毒症小鼠模型中评估TanIIA的体内治疗效果。体外使用脂多糖(LPS)处理的BEAS-2B细胞来阐明潜在机制。通过蛋白质免疫印迹法、定量逆转录聚合酶链反应(qRT-PCR)、免疫组织化学、流式细胞术和线粒体功能测定来评估基因表达、细胞凋亡和线粒体功能。
VEGFR2被确定为TanIIA在SILI中的关键治疗靶点。TanIIA治疗显著提高了盲肠结扎穿孔(CLP)诱导的脓毒症小鼠的存活率,减轻了肺组织病理学损伤,并降低了促炎细胞因子水平。机制上,TanIIA抑制VEGFR2-磷脂酰肌醇-3-激酶(PI3K)-蛋白激酶B(AKT)信号通路,维持线粒体完整性并抑制细胞凋亡。使用LPS处理的BEAS-2B上皮细胞进行的进一步验证强化了最初的发现。
TanIIA通过特异性靶向VEGFR2并抑制PI3K/AKT信号通路,对SILI具有保护作用,这有助于维持线粒体稳态并减少细胞凋亡。